- recruitingPHASE3
Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders
This study is looking into whether a drug called rituximab can help people with a rare nerve condition called anti-MAG neuropathy. Doctors want to see if it works for specific patients who might respond better, based on previous research.
France - authorisedTherapeutic confirmatory (Phase III)
Rituximab therapy in anti-MAG patients with characteristics of good responders: THERAMAG study
This study looks at whether a medicine called rituximab, given with salt water, can help people in the UK with a nerve condition called anti-MAG neuropathy. Researchers want to see if it improves their symptoms over 12 months.
France